Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico

Contexto: La eficacia de los cannabinoides en el dolor neuropático es desconocida. El control del dolor es determinante en los pacientes ya que genera un impacto negativo en la calidad de vida de los pacientes. Objetivo: El presente trabajo pretende demostrar la evidencia sobre la eficacia de los...

Descripción completa

Detalles Bibliográficos
Autores Principales: Barbosa Villada, Maria, Borda Restrepo, Diana
Otros Autores: Hernandez-Castro, John-Jairo
Formato: Tesis de maestría (Master Thesis)
Lenguaje:Español (Spanish)
Publicado: Universidad del Rosario 2016
Materias:
Acceso en línea:http://repository.urosario.edu.co/handle/10336/12311
id ir-10336-12311
recordtype dspace
institution EdocUR - Universidad del Rosario
collection DSpace
language Español (Spanish)
topic Cáncer
Dolor Neuropático por cáncer
Cannabinoides
Fisiología humana
Cancer
Neuropathic pain
Oncologic pain
Cannabinoids
Oncología Médica
Cannabinoides
Neuralgia
Dolor Crónico
Cannabis
spellingShingle Cáncer
Dolor Neuropático por cáncer
Cannabinoides
Fisiología humana
Cancer
Neuropathic pain
Oncologic pain
Cannabinoids
Oncología Médica
Cannabinoides
Neuralgia
Dolor Crónico
Cannabis
Barbosa Villada, Maria
Borda Restrepo, Diana
Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
description Contexto: La eficacia de los cannabinoides en el dolor neuropático es desconocida. El control del dolor es determinante en los pacientes ya que genera un impacto negativo en la calidad de vida de los pacientes. Objetivo: El presente trabajo pretende demostrar la evidencia sobre la eficacia de los medicamentos cannabinoides en el control del dolor neuropático oncológico, mediante la evaluación de la literatura disponible. Metodología: Se realizó una revisión sistemática de literatura incluyendo estudios experimentales, observacionales y revisiones sistemáticas en un periodo de 15 años. Se incluyeron todos los estudios desde el años 2000 con evidencia IB según la escala de evidencia de Oxford. Resultados: Cuatro estudios cumplieron criterios para su inclusión, sin embargo la evidencia es baja y no permite recomendar o descartar los cannabinoides como terapia coadyuvante en control del dolor neuropático oncológico. La combinación de THC/CDB (Sativex®) parece ser un medicamento seguro pues no se reportaron muertes asociadas a su uso, sin embargo la presentación de eventos adversos a nivel gastrointestinal y neurológico podría aumentar el riesgo de interacciones medicamentosas y tener un impacto negativo en la calidad de vida de los pacientes oncológicos. Conclusiones: No hay suficiente literatura y la evidencia no es suficiente para recomendar o descartar el uso de los cannabinoides en dolor neuropático oncológico. Futuros estudios deben realizarse para analizar el beneficio de estos medicamentos. Aunque ética y socialmente hay resistencia para el uso de los cannabinoides, actualmente hay una gran discusión política en el mundo y en Colombia para su aceptación como terapia en el control del dolor.
author2 Hernandez-Castro, John-Jairo
author_facet Hernandez-Castro, John-Jairo
Barbosa Villada, Maria
Borda Restrepo, Diana
format Tesis de maestría (Master Thesis)
author Barbosa Villada, Maria
Borda Restrepo, Diana
author_sort Barbosa Villada, Maria
title Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
title_short Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
title_full Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
title_fullStr Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
title_full_unstemmed Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
title_sort evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico
publisher Universidad del Rosario
publishDate 2016
url http://repository.urosario.edu.co/handle/10336/12311
_version_ 1694382407715651584
spelling ir-10336-123112021-03-01T19:22:55Z Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico Barbosa Villada, Maria Borda Restrepo, Diana Hernandez-Castro, John-Jairo Cáncer Dolor Neuropático por cáncer Cannabinoides Fisiología humana Cancer Neuropathic pain Oncologic pain Cannabinoids Oncología Médica Cannabinoides Neuralgia Dolor Crónico Cannabis Contexto: La eficacia de los cannabinoides en el dolor neuropático es desconocida. El control del dolor es determinante en los pacientes ya que genera un impacto negativo en la calidad de vida de los pacientes. Objetivo: El presente trabajo pretende demostrar la evidencia sobre la eficacia de los medicamentos cannabinoides en el control del dolor neuropático oncológico, mediante la evaluación de la literatura disponible. Metodología: Se realizó una revisión sistemática de literatura incluyendo estudios experimentales, observacionales y revisiones sistemáticas en un periodo de 15 años. Se incluyeron todos los estudios desde el años 2000 con evidencia IB según la escala de evidencia de Oxford. Resultados: Cuatro estudios cumplieron criterios para su inclusión, sin embargo la evidencia es baja y no permite recomendar o descartar los cannabinoides como terapia coadyuvante en control del dolor neuropático oncológico. La combinación de THC/CDB (Sativex®) parece ser un medicamento seguro pues no se reportaron muertes asociadas a su uso, sin embargo la presentación de eventos adversos a nivel gastrointestinal y neurológico podría aumentar el riesgo de interacciones medicamentosas y tener un impacto negativo en la calidad de vida de los pacientes oncológicos. Conclusiones: No hay suficiente literatura y la evidencia no es suficiente para recomendar o descartar el uso de los cannabinoides en dolor neuropático oncológico. Futuros estudios deben realizarse para analizar el beneficio de estos medicamentos. Aunque ética y socialmente hay resistencia para el uso de los cannabinoides, actualmente hay una gran discusión política en el mundo y en Colombia para su aceptación como terapia en el control del dolor. Background: The efficacy of cannabinoids in neuropathic pain is still unknown. Pain management is critical for patients because it creates a negative impact on the quality of life of patients. Objective: This study aims to demonstrate the evidence towards the effectiveness of cannabinoid drugs in controlling oncological neuropathic pain, by evaluating the available literature. Methodology: A systematic review of literature was conducted including experimental, observational studies and systematic reviews over a period of 15 years All studies since 2000 with Oxford evidence scale as IB were included. Results: Four studies met criteria for its inclusion, but the evidence is low and does not allow to recommend or discard cannabinoids as adjunctive therapy in cancer control neuropathic pain. The combination of THC / CBD (Sativex) appears to be safe for its use, and is not associated with deaths reported, however the presentation of adverse gastrointestinal and neurological level events could increase the risk of drug interactions and have a negative impact on the quality of life of cancer patients. Conclusions: There is not enough literature and evidence is not sufficient to recommend or discard the use of cannabinoids in neuropathic cancer pain. Future studies should be conducted to analyze the benefit of these drugs. Although ethically and socially there is resistance to the use of cannabinoids, there is currently a great political discussion in the world and in Colombia for acceptance as therapy in pain control. 2016-08-04 2016-08-30T19:33:53Z info:eu-repo/semantics/masterThesis info:eu-repo/semantics/acceptedVersion http://repository.urosario.edu.co/handle/10336/12311 spa http://creativecommons.org/licenses/by-nc-nd/2.5/co/ info:eu-repo/semantics/openAccess application/pdf Universidad del Rosario Toxicología Clínica Facultad de Medicina instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012 Poulin PA, Romanow HC, Rahbari N, Small R, Smyth CE, Hatchard T, et al. The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain. Support Care Cancer [Internet]. 2016 May 18 [cited 2016 Jun 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27193116 Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics [Internet]. 2009 Oct [cited 2016 Jun 3];6(4):713–37. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2755639&tool=pmcentrez&rendertype=abstract Rahn EJ, Makriyannis a, Hohmann a G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol [Internet]. 2007;152(5):765–77. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2190028&tool=pmcentrez&rendertype=abstrac Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol [Internet]. 2010 Feb [cited 2016 Jun 3];10(1):80–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2818338&tool=pmcentrez&rendertype=abstract Urch CE, Dickenson a H. Neuropathic pain in cancer. Eur J Cancer [Internet]. 2008;44:1091–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18492553 Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med [Internet]. 2013;27:714–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23175513 OMS. Envejecimiento activo: un marco político. Rev Española Geriatría y Gerontol. 2002;37(2):74–105 Patel NB. Guide to Pain Management in Low-Resource Settings. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol [Internet]. 2012 Oct [cited 2015 Apr 30];23 Suppl 7(Supplement 7):vii139–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22997447 Ed M, Midbari a, Eisenberg E, Mcnicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain ( Review ) Opioids for neuropathic pain. 2013;(9):9–11. Manuel Gonzalez Barón. ANALES REAL ACADEMIA NACIONAL DE MEDICINA. 2000. Vacia L silla. Proyecto de Galán (Lo que dijo santos y todos los estudios y linea histórica que ayudan a argumentar a Galan) [Internet]. Available from: http://lasillavacia.com/sites/default/files/files/SEGUNDO PROYECTO AL 02 DE 2009 VF(1). MPS Ministerio de la Protección social. Decreto Número 2467 de 2015. El ABC del decreto. Ministerio de salud (el abc del decreto) [Internet]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/abc-canabis. Alejandro Gaviria Uribe. La marihuana con uso terapéutico en el contexto colombiano. Ministerio de Salud y Protección Social. 2014 Revista Semana. Noticias sobre la ley [Internet]. Available from: http://www.semana.com/nacion/articulo/marihuana-medicinal-es-aprobada-en-el-congreso/475155 Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci [Internet]. 2016;7(February):19. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4740396&tool=pmcentrez&rendertype=abstract Guerriero G, Hausman JF, Strauss J, Ertan H, Siddiqui KS. Lignocellulosic biomass: Biosynthesis, degradation, and industrial utilization. Eng Life Sci. 2016;16(1):1–16. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–8 Kiran Vemuri V, Makriyannis A. Medicinal Chemistry of Cannabinoids. Clin Pharmacol Ther. 2015;97(6):553–8 Niesink RJM, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front psychiatry [Internet]. 2013;4(October):130 Harris CR, Brown A. Synthetic cannabinoid intoxication: A case series and review. J Emerg Med [Internet]. Elsevier Ltd; 2013;44(2):360–6. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry. 2009;21(2):113–21 Devane W a, Hanus L, Breuer A, Pertwee RG, Stevenson L a, Griffin G, et al. Constituent Receptor. Science (80- ). 1992;258(10):1946–9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature [Internet]. 1990 Aug 9 [cited 2015 Jan 27];346(6284):561–4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature [Internet]. 1993 Sep 2 [cited 2014 Dec 14];365(6441):61–5. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 2001;29(3):717–27. Wilson RI, Nicoll R a. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588–92. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci [Internet]. 2001;356(1407):381–408. Guindon J, Hohmann a G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319–34. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A [Internet]. 1990;87(5):1932–6. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience [Internet]. 1998 Jul [cited 2016 May 26];85(2):395–403. Lévénés C, Daniel H, Soubrié P, Crépel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol [Internet]. 1998 Aug 1 [cited 2016 May 26];510 ( Pt 3:867–79. Jennings EA, Vaughan CW, Christie MJ. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol. 2001;534(3):805–12. Gifford AN, Ashby CR. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther [Internet]. 1996 Jun [cited 2016 May 26];277(3):1431–6. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol [Internet]. 1996 Aug [cited 2016 May 26];118(8):2023–8. Cadogan AK, Alexander SP, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem [Internet]. 1997 Sep [cited 2016 May 26];69(3):1131–7. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(1):19–24. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci [Internet]. 2006 Mar [cited 2016 May 26];23(6):1530–8. Ts-- S, Shaaban KA, Singh S, Elshahawi SI, Wang X, Larissa V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. 2014;67(3):223–30. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309–80 Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci [Internet]. 2002 May 15 [cited 2016 May 26];22(10):3864–72. Kano M, Ohno-shosaku T, Hashimotodani Y. Endocannabinoid-Mediated Control of Synaptic Transmission. 2009;309–80. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol [Internet]. 2007 Dec [cited 2016 Apr 6];152(7):1092–101 Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther [Internet]. 2007 Apr [cited 2016 Apr 3];114(1):13–33. Jones RCW, Lawson E, Backonja M. Managing Neuropathic Pain. Med Clin North Am. 2016;100(1):151–67. Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol. 2013;27(1):64–80. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61(1):149–60. Romero TRL, Resende LC, Guzzo LS, Duarte IDG. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg. 2013;116(2):463–72. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain [Internet]. 1998 Mar [cited 2016 May 26];75(1):111–9. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A [Internet]. 2005;102(8):3093–8. Schmidt BL, Schmidt BL. The Neurobiology of Cancer Pain\r. 2014;(March). IASP Taxonomy 2012 update [Internet]. IASP Taxonomy. 2012. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698 Board E. Diagnosis and Classifi cation of Neuropathic Pain Epidemiology and Impact of Neuropathic Pain. Pain Med. 2010;XVIII(7):1–6 Dubin AE, Patapoutian A. Nociceptors: The sensors of the pain pathway. Journal of Clinical Investigation. 2010. p. 3760–72 Woolf CJ, Ma Q. Nociceptors-Noxious Stimulus Detectors. Neuron. 2007;55(3):353–64. Rathmell JP, Hill B. Wall and Melzack’s Textbook of Pain, 5th E-dition. Anesth Analg [Internet]. 2006;102(6). Available from: http://journals.lww.com/anesthesia-analgesia/Fulltext/2006/06000/Wall_and_Melzack_s_Textbook_of_Pain,_5th_E_dition_.78.aspx Tracey I, Mantyh PW. The Cerebral Signature for Pain Perception and Its Modulation. Neuron. 2007;55(3):377–91. Romera E, Perena MJ, Rodrigo MFPMD. Neurofisiología del dolor. Rev Soc Esp Dolor. 2000;7(II):11–7. Ossipov MH, Dussor GO, Porreca F. Review series Central modulation of pain. J Clin Invest. 2010;120(11):3779–87. Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract [Internet]. 2012;12:219–51. Mols F, Beijers T, Vreugdenhil G, Van De Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer. 2014;22(8):2261–9. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67 Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–15. Park SB, Goldstein D, Krishnan A V, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin [Internet]. 2013;63(6):419–37. Article R. Chemotherapy-induced peripheral neuropathy : review for clinical practice *. 2015;16(3):215–20 Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002;23(3):239–55. Downie WW, Leatham P a, Rhind VM, Wright V, Branco J a, Anderson J a. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378–81. Plancarte Sánchez R, Guajardo Rosas J, Guillén Nuñez R. Manejo integral del dolor. Cancerología. 2006;1:273–81. Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ [Internet]. 2008;178(13):1669–78 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez A V, et al. Cannabinoids for Medical Use. Jama [Internet]. 2015;313(24):2456. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs [Internet]. 2008 Jan [cited 2016 May 26];22(4):291–324. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007;68(7):515–21. Johnson JR, Chb MB, Burnell-nugent M, Bchir MB, Lossignol D, Chb MB, et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain - pdf. 2010;39(2):167–79. Merskey H, Bogduk N. Classification of Chronic Pain. IASP Pain Terminology. 1994. 240 p. M. FJYJJLLWJP. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical rating scale. Pain. 2001;94(2):149–58. ministerio de salud y proteccion social I. ABC Seguridad 2014. ABC-Seguridad en el uso Medicam [Internet]. 2016;10–30. William; Sackett, David L; Straus SER. Evidence-based medicine: How to practice and teach EBM. 2000. 1-27 p Welch V, Petticrew M, Tugwell P, Moher D, Neill JO, Waters E et al. Extensión PRISMA-Equidad 2012 : guías para la escritura y la publicación de revisiones sistemáticas enfocadas en la equidad en salud. Rev Panam Salud Pública. 2013;34(4):60–8. MPS Ministerio de la Protección social. Resolucion 8430/1993 Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación á. Bogotá. 1993. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther [Internet]. 2011;90(6):844–51. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 1999;289(2):859–67. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Cmaj. 2010;182(14). Ramaekers JG, van Wel JH, Spronk DB, Toennes SW, Kuypers KPC, Theunissen EL, et al. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Sci Rep [Internet]. Nature Publishing Group; 2016;6(May):26843. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. Elsevier Inc; 2014;47(1):166–73 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain [Internet]. International Association for the Study of Pain; 2010;150(3):573–81. Available from: http://dx.doi.org/10.1016/j.pain.2010.06.019 Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49. Clark J, Cunningham M, McMillan S, Vena C, Parker K. Sleep-wake disturbances in people with cancer part II: evaluating the evidence for clinical decision making. Oncol Nurs Forum. 2004;31(4):747–71. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–18. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506–21. Cancer, Neuropathic cancer pain, cannabinoids, Neuropathic pain, oncologic pain Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2009;285(1):6–12.
score 12,131701